Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

VX-787 is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. Viral genetics and X-ray crystallography studies provide support for the idea that VX-787 occupies the 7-methyl GTP (m(7)GTP) cap-binding site of PB2. VX-7...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Antimicrob Agents Chemother
Asıl Yazarlar: Byrn, Randal A., Jones, Steven M., Bennett, Hamilton B., Bral, Chris, Clark, Michael P., Jacobs, Marc D., Kwong, Ann D., Ledeboer, Mark W., Leeman, Joshua R., McNeil, Colleen F., Murcko, Mark A., Nezami, Azin, Perola, Emanuele, Rijnbrand, Rene, Saxena, Kumkum, Tsai, Alice W., Zhou, Yi, Charifson, Paul S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2015
Konular:
Antiviral Agents
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4325764/
https://ncbi.nlm.nih.gov/pubmed/25547360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04623-14
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller